Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?

Amgen (AMGN) shares rose 3.5% to $285.41 on strong volume following an advisory committee's recommendation to the European Medicine Agency for expanding Uplizna's use to treat immunoglobulin G4-related disease, a rare autoimmune condition with no approved therapies in the EU. This development, supported by positive Phase III data, suggests a significant market opportunity for the drug. However, the company faces a projected 10.2% year-over-year decline in upcoming quarterly EPS, despite a 5% revenue increase, and recent consensus EPS estimates have been revised down by 1.6%, potentially tempering sustained upward momentum.

Analysis

Amgen (AMGN) shares experienced a 3.5% single-session increase to $285.41 on significant volume, a move largely attributed to a positive regulatory development. An advisory committee to the European Medicine Agency recommended expanding the use of Amgen's drug, Uplizna, for a rare autoimmune condition with no currently approved therapies in the EU, signaling a potentially untapped market. This positive catalyst, however, is contrasted by a challenging near-term fundamental outlook. The company is projected to report a 10.2% year-over-year decline in quarterly earnings per share to $5.01, even as revenues are expected to grow 5% to $8.93 billion. Critically, consensus EPS estimates for the quarter have been revised downward by 1.6% over the last 30 days, a trend that empirical research suggests is often a precursor to near-term stock price weakness. This recent stock jump follows a 6.7% decline over the past four weeks, indicating the current positive momentum is battling against underlying negative sentiment regarding profitability.

Key Decisions for Investors

• Investors should weigh the long-term potential of the positive regulatory news for Uplizna against the significant near-term headwind of a projected 10.2% YoY decline in earnings.
• The 1.6% downward revision in consensus EPS estimates is a key bearish signal that may temper the stock's upward momentum, warranting caution ahead of the upcoming earnings report.
• Consider the recent 3.5% price jump in the context of the stock's 6.7% loss over the prior four weeks, as sustaining this rally may depend on the company overcoming the lowered earnings expectations.